XBIO
Xenetic Biosciences, Inc.Company Information
- Company Name
- Xenetic Biosciences, Inc.
- CIK
- CIK0001534525
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- XBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- XBIO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 149,395
- Shares outstanding
- 2,294,364
- Ownership
- 6.51%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 39.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | - | 7 | - | - | - | 5 | 6 | 7 | 7 | 8 | 9 | 10 | ||||||
| Cash And Cash Equivalents At Carrying Value | 6 | 7 | 8 | 4 | 5 | 5 | 6 | 7 | 7 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 7 | 8 | 8 | 5 | 5 | 5 | 7 | 7 | 8 | 8 | 10 | 11 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 7 | 8 | 8 | 5 | 5 | 6 | 7 | 8 | 9 | 9 | 11 | 12 | ||||||
| Accounts Payable Current | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
| Commitments And Contingencies | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 212 | 212 | 212 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | ||||||
| Retained Earnings Accumulated Deficit | -201 | -200 | -200 | -199 | -199 | -198 | -197 | -196 | -196 | -194 | -193 | -192 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Value | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | ||||||
| Stockholders Equity | 6 | 7 | 7 | 4 | 4 | 5 | 6 | 7 | 7 | 9 | 10 | 11 | ||||||
| Liabilities And Stockholders Equity | 7 | 8 | 8 | 5 | 5 | 6 | 7 | 8 | 9 | 9 | 11 | 12 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialXenetic Biosciences, Inc. (XBIO) — SEC Financial Statements & Analysis
Xenetic Biosciences, Inc. (XBIO) is a pharmaceutical preparations company, incorporated in NV. Xenetic Biosciences, Inc. trades on Nasdaq as: XBIO. Xenetic Biosciences, Inc. (XBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Xenetic Biosciences, Inc. carries a market cap of $6.68M, a P/E ratio of -2.70x, a P/B ratio of 1.10x, a P/S ratio of 2.05x, an enterprise value of $204.83K, and an EV/EBITDA multiple of -0.08x. On profitability, it posts an operating margin of -81.01%, a net margin of -75.91%, a Return on Equity (ROE) of -47.04%, a Return on Assets (ROA) of -40.17%, and a Return on Invested Capital (ROIC) of -848.61%. Per share, it reports EPS of $-1.08, diluted EPS of $-1.08, free cash flow per share of $-1.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 33.30% year-over-year, net income growth of -19.72% year-over-year, and EPS growth of -46.04% year-over-year. On the balance sheet, it maintains a current ratio of 7.43x, a quick ratio of 7.23x, working capital of $5.76M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, an interest coverage ratio of -35.42x, free cash flow of $-2.31M (TTM), and net debt of $-6.47M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.68M
- P/E TTM
- -2.70x
- EPS TTM
- $-1.08
- P/B TTM
- 1.10x
- ROE TTM
- -47.04%
- ROA TTM
- -40.17%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-2.31M
- Net Revenue TTM Growth 1Y
- 33.30%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Xenetic Biosciences, Inc. in?
Xenetic Biosciences, Inc. (XBIO) operates in the Pharmaceutical Preparations industry.
What exchange does XBIO trade on?
Xenetic Biosciences, Inc. (XBIO) trades on the Nasdaq.
Where is Xenetic Biosciences, Inc. incorporated?
Xenetic Biosciences, Inc. is incorporated in NV.
When was Xenetic Biosciences, Inc. (XBIO)'s most recent SEC filing?
Xenetic Biosciences, Inc. (XBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is XBIO's market cap?
Xenetic Biosciences, Inc. (XBIO) has a market capitalization of $6.68M as of 2026-06-30.
What is XBIO's EPS (earnings per share)?
Xenetic Biosciences, Inc. (XBIO)'s trailing twelve month EPS is $-1.08 as of 2026-06-30.
What is XBIO's ROE (return on equity)?
Xenetic Biosciences, Inc. (XBIO)'s trailing twelve month Return on Equity (ROE) is -47.04% as of 2026-06-30.
What is XBIO's ROA (return on assets)?
Xenetic Biosciences, Inc. (XBIO)'s trailing twelve month Return on Assets (ROA) is -40.17% as of 2026-06-30.
What is XBIO's ROIC (return on invested capital)?
Xenetic Biosciences, Inc. (XBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -848.61% as of 2025-03-31.
What is XBIO's EV/EBITDA?
Xenetic Biosciences, Inc. (XBIO)'s trailing twelve month EV/EBITDA is -0.08x as of 2026-06-30.